biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT
4D Molecular Therapeutics
4D Molecular Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 5858 Horton St, 455, Emeryville, California 94608, US
- Founded
- 2013
- Employees
- 213
- Programs
- 19
- Drugs
- 13
- Patents
- 15
4D Molecular Therapeutics projects
3 ClinicalTrials.gov programs sponsored by 4D Molecular Therapeutics.
4D Molecular Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
4D-150 IVT (3E10 vg/eye)
4D Molecular Therapeutics
Macular Neovascularization Secondary to Age-Related Macular Degeneration
1 trial -
4D-150 IVT (3E10 vg/eye)
4D Molecular Therapeutics
Neovascular Age-Related Macular Degeneration (nAMD)
1 trial -
4D-150-C004
4D Molecular Therapeutics
Macular neovascularization secondary to age-related macular degeneration (nAMD)
1 trial
Frequently asked questions
How many clinical projects does 4D Molecular Therapeutics have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.